Canada - English - Health Canada

sandoz canada incorporated - dimethyl fumarate - capsule (delayed release) - 240mg - dimethyl fumarate 240mg - miscellaneous central nervous system agents

Canada - English - Health Canada

jamp pharma corporation - dimethyl fumarate - capsule (delayed release) - 120mg - dimethyl fumarate 120mg - miscellaneous central nervous system agents

Canada - English - Health Canada

jamp pharma corporation - dimethyl fumarate - capsule (delayed release) - 240mg - dimethyl fumarate 240mg - miscellaneous central nervous system agents

Canada - English - Health Canada

sandoz canada incorporated - dimethyl fumarate - capsule (delayed release) - 120mg - dimethyl fumarate 120mg - miscellaneous central nervous system agents

Canada - English - Health Canada

sandoz canada incorporated - dimethyl fumarate - capsule (delayed release) - 240mg - dimethyl fumarate 240mg - miscellaneous central nervous system agents

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, enteric - excipient ingredients: croscarmellose sodium; gelatin; purified talc; magnesium stearate; iron oxide yellow; silicified microcrystalline cellulose; triethyl citrate; titanium dioxide; brilliant blue fcf; methacrylic acid copolymer; colloidal anhydrous silica; iron oxide black; methacrylic acid - ethyl acrylate copolymer (1:1); propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - dimethyl fumarate enteric coated capsules are indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, enteric - excipient ingredients: croscarmellose sodium; gelatin; purified talc; magnesium stearate; iron oxide yellow; silicified microcrystalline cellulose; triethyl citrate; titanium dioxide; brilliant blue fcf; methacrylic acid copolymer; colloidal anhydrous silica; iron oxide black; methacrylic acid - ethyl acrylate copolymer (1:1); propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - dimethyl fumarate enteric coated capsules are indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, enteric - excipient ingredients: croscarmellose sodium; gelatin; purified talc; magnesium stearate; iron oxide yellow; silicified microcrystalline cellulose; triethyl citrate; titanium dioxide; brilliant blue fcf; methacrylic acid copolymer; colloidal anhydrous silica; iron oxide black; methacrylic acid - ethyl acrylate copolymer (1:1); propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - dimethyl fumarate enteric coated capsules are indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, enteric - excipient ingredients: croscarmellose sodium; gelatin; purified talc; magnesium stearate; iron oxide yellow; silicified microcrystalline cellulose; triethyl citrate; titanium dioxide; brilliant blue fcf; methacrylic acid copolymer; colloidal anhydrous silica; iron oxide black; methacrylic acid - ethyl acrylate copolymer (1:1); propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - dimethyl fumarate enteric coated capsules are indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - dimethyl fumarate 120mg - modified release capsule - 120 mg - active: dimethyl fumarate 120mg excipient: colloidal silicon dioxide croscarmellose sodium ethanol gelatin   indigo carmine iron oxide black iron oxide yellow magnesium stearate methacrylic acid - ethyl acrylate copolymer methacrylic acid copolymer microcrystalline cellulose opacode black s-1-17822 purified talc silicified microcrystalline cellulose titanium dioxide   triethyl citrate   - dimethyl fumarate viatris is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.